<DOC>
	<DOCNO>NCT00351559</DOCNO>
	<brief_summary>This study design evaluate safety efficacy leukocyte gene expression profile method monitoring asymptomatic heart transplant patient acute rejection .</brief_summary>
	<brief_title>IMAGE : A Comparison AlloMap Molecular Testing Traditional Biopsy-based Surveillance Heart Transplant Rejection</brief_title>
	<detailed_description>Cardiac allograft rejection experience 20-50 % patient least first year cardiac transplantation present immunosuppression regimen . With high incidence acute cellular rejection ( ACR ) first six month post-transplant , ACR continue occur beyond first year post-transplant . However , optimal strategy detect rejection period low risk period ACR still controversial . The standard rejection surveillance endomyocardial biopsy ( EMB ) . However , EMB invasive , cause morbidity , subject sample error inter-observer variability . Gene expression profile ( GEP ) , high negative predictive value ( NPV ) acute cellular rejection ( ACR ) , appear well suit identify low-risk patient safely manage without routine invasive endomyocardial biopsy ( EMB ) .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<criteria>1 . Heart transplant recipient &gt; 6 month 5 year ( &gt; 660 month ) posttransplant . 2 . Age ≥ 18 year . 3 . Stable outpatient see routine monitoring rejection . Stability define absence prior current evidence either severe cardiac allograft vasculopathy ( CAV ) antibodymediated rejection ( AMR ) associate hemodynamic compromise . 1 . Severe CAV define either &gt; 50 % leave main stenosis ; ≥ 50 % stenosis ≥ 2 primary vessel ( proximal 1/3 middle 1/3 LAD LCx , RCA takeoff PDA rightdominant coronary circulation ) Isolated branch stenosis &gt; 50 % 3 system ( diagonal branch , obtuse marginal branch , distal 1/3 LAD LCx , PDA , PLB , RCA takeoff PDA nondominant system ) . 2 . AMR associate hemodynamic compromise define AMR ( define accord local criterion ) either A left ventricular ejection fraction ( LVEF ) ≤ 30 % least 25 % low baseline value , A cardiac index &lt; 2 l/min/m2 , The use inotropic agent support circulation . 4 . Left ventricular ejection fraction ≥ 45 % Echocardiography , Multiple Gated Acquisition ( MUGA ) scan , ventriculography study entry ( baseline / enrollment study ) . 1 . Patients &lt; 7 calendar month heart transplantation . 2 . Any clinical sign decline graft function : 1 . Symptoms Congestive Heart Failure ( CHF ) enrollment visit . 2 . Signs decompensated heart failure , include development new S3 gallop enrollment visit . 3 . Elevated right heart pressure diminish cardiac index &lt; 2.2 L/min/m2 new compare previous measurement within 6 month . 4 . Decrease LVEF measure echocardiography : ≥ 25 % compare prior measurement within 6 month . 3 . Rejection therapy biopsyproven ISHLT Grade 3A high precede 2 month . 4 . Major change immunosuppression therapy within previous 30 day ( e.g. , discontinuation calcineurin inhibitor , switch mycophenolate mofetil sirolimus vice versa ) . 5 . Unable give write informed consent . 6 . Patient receive hematopoietic growth factor ( e.g. , Neupogen , Epogen ) currently previous 30 day . 7 . Patients receive ≥ 20 mg/day prednisone equivalent corticosteroid time enrollment . 8 . Patient enrol trial require routine surveillance endomyocardial biopsy . 9 . Patient receive transfusion within precede 4 week . 10 . Patients endstage renal disease require form renal replacement therapy ( hemodialysis peritoneal dialysis ) . 11 . Pregnancy time enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>allograft</keyword>
	<keyword>rejection</keyword>
	<keyword>biopsy</keyword>
	<keyword>gene</keyword>
	<keyword>expression</keyword>
	<keyword>cardiac</keyword>
	<keyword>heart</keyword>
	<keyword>transplant</keyword>
</DOC>